En­trada's Duchenne study re­mains on hold in US as biotech com­pletes dos­ing of two co­horts in UK tri­al

En­tra­da Ther­a­peu­tics an­nounced that it com­plet­ed dos­ing for two co­horts for a Phase I study of an ex­per­i­men­tal Duchenne mus­cu­lar dy­s­tro­phy drug that it’s con­duct­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER